Home
About BioMark
Oncology Platform
- Biomark SSAT1 Assay
- BioMark Metabolic Panel
Investor Relations
Bio-Stream Diagnostics
- Bio-Stream Spectral Test
Recent Posts
Info & Contact

News Releases

« Back to News

Biomark Secures DTC Eligibility

May 28, 2015

Press Release – BIOMARK SECURES DTC ELIGIBILITY (PDF)

———————————————

< BioMark Receives No Objection Letter From Health Canada BioMark Diagnostics Engages LHA for Investors Relations >

ARCHIVES

2019 News Release
2018 News Release
2017 News Release
2016 News Release
2015 News Release
2014 News Release

Further information about BioMark is available under its profile on:

SEDAR website:

http://www.sedar.com

CSE website:

http://thecse.com

Sitemap

Home
About BioMark
Oncology Platform
- Biomark SSAT1 Assay
- BioMark Metabolic Panel
Investor Relations
Bio-Stream Diagnostics
- Bio-Stream Spectral Test
Recent Posts
Info & Contact

Latest Posts

Richmond company looking for ‘holy grail’ in COVID-19 testing
Dr. Horacio Bach – receives major grant from CIHR for COVID-19 antibody development
BIOMARK’S LIQUID BIOPSY SCIENTIFIC PAPER TO BE FEATURED AS COVER ON CANCERS UPCOMING ISSUE
National research team targets glioblastoma
BIOMARK’S ABSTRACT FOR 2019 ASCO ONLINE PUBLICATION

Site Policies

Terms and Conditions
Website and Privacy Policy

Contact Us

INVESTOR CORPORATE INQUIRES

RASHID A. BUX

CEO
604.370.0779
info@biomarkdiagnostics.com

Copyright © 2019 BioMark Diagnostics Inc. All rights reserved.

BioMark's mission is to provide universal access to a new paradigm in cancer diagnostics using metabolomics.